Ascendis Pharma A/S

ASND

US04351P1012

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:57:47 17/09/2024 BST			5-day change	1st Jan Change
143.72 ^USD	+2.98%		+25.93%	+14.74%

05:24pm	European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading	MT
02:26pm	Oppenheimer Raises Ascendis Pharma A/S Price Target to $190 From $180, Maintains Outperform Rating	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Ascendis Pharma A/S

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading	04:24pm	MT
Oppenheimer Raises Ascendis Pharma A/S Price Target to $190 From $180, Maintains Outperform Rating	01:26pm	MT
Evercore Raises Price Target on Ascendis Pharma to $205 From $191, Keeps Outperform Rating	01:00pm	MT
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	09-16	MT
Ascendis Pharma Says Trial of Potential Dwarfism Drug Achieved Primary Endpoint	09-16	MT
Transcript : Ascendis Pharma A/S - Special Call	09-16
Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo	09-16	CI
European Equities Close Higher on Friday; HSBC Mulls Potential Sale of South African Unit	09-13	MT
Ascendis Says Initial Data Shows Anti-Tumor Activity in Phase 1/2 Platinum-Resistant Ovarian Cancer Trial	09-13	MT
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024	09-13	CI
Ascendis Pharma Gets FDA Orphan Drug Designation for Hypoparathyroidism Treatment	09-12	MT
Ascendis Pharma Gets Orphan Drug Exclusivity for Hormone Treatment Yorvipath in U.S.	09-11	DJ
Oppenheimer Upgrades Ascendis Pharma A/S to Outperform From Perform, $180 Price Target	09-05	MT
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading	09-04	MT
Sector Update: Health Care Stocks Fall Premarket Wednesday	09-04	MT
Royalty Pharma, Ascendis Pharma Unit Have $150 Million Royalty Funding Agreement	09-03	MT
Ascendis Pharma Q2 Loss Narrows, Sales Slump -- Shares Plunge After Hours	09-03	MT
Earnings Flash (ASND) ASCENDIS PHARMA Reports Q2 Revenue EUR36M	09-03	MT
Ascendis Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	09-03	CI
Transcript : Ascendis Pharma A/S, Q2 2024 Earnings Call, Sep 03, 2024	09-03
Evercore ISI Raises Price Target on Ascendis Pharma to $200 From $191, Keeps Outperform Rating	08-26	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	08-22	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	08-13	MT
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading	08-12	MT
Sector Update: Health Care Stocks Flat to Higher Pre-bell Monday	08-12	MT

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Employees

879

Sector

Biotechnology & Medical Research

Calendar

05/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company